Amgen Inc. v. Sanofi
Petition for certiorari denied on January 7, 2019
Issue: Whether the standard for determining the adequacy of the “written description of the invention” in a patent must be “in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains . . . to make and use the same,” as stated within the Patent Act, 35 U.S.C. § 112(a), or whether court-created standards should control instead.
| Date | Proceedings and Orders (key to color coding) |
|---|
| May 11 2018 | Application (17A1262) to extend the time to file a petition for a writ of certiorari from May 24, 2018 to July 23, 2018, submitted to The Chief Justice. |
| May 14 2018 | Application (17A1262) granted by The Chief Justice extending the time to file until July 23, 2018. |
| Jul 23 2018 | Petition for a writ of certiorari filed. (Response due August 27, 2018) |
| Aug 27 2018 | Brief amici curiae of Bristol-Myers Squibb Company, Morphosys AG, Bavarian Nordic A/S, and UCB Biopharma SPRL filed. |
| Sep 12 2018 | DISTRIBUTED for Conference of 10/5/2018. |
| Sep 18 2018 | Response Requested. (Due October 18, 2018) |
| Sep 20 2018 | Motion to extend the time to file a response is granted and the time is extended to and including November 19, 2018 |
| Sep 20 2018 | Motion to extend the time to file a response from October 18, 2018 to November 17, 2018, submitted to The Clerk. |
| Nov 19 2018 | Brief of respondents Sanofi, et al. in opposition filed. |
| Dec 04 2018 | Reply of petitioners Amgen Inc., et al. filed. (Distributed) |
| Dec 05 2018 | DISTRIBUTED for Conference of 1/4/2019. |
| Jan 07 2019 | Petition DENIED. |
